New concepts in dyslipidemia in the metabolic syndrome and diabetes
Related Experiment Videos
Michael H Davidson1, H Daniel Yannicelli
1Preventive Cardiology Center, Rush University Medical Center, Chicago, Illinois.
Insights
Cardiovascular risk is unevenly distributed, with diabetic patients with prior cardiovascular disease (CVD) at highest risk. Combating insulin resistance through lifestyle changes and medications like fibrates can significantly lower this risk.
Area of Science:
- Cardiology
- Endocrinology
- Metabolic Syndrome Research
Background:
- Cardiovascular risk is not uniform, forming a
- risk pyramid
- with diabetic patients with prior cardiovascular disease (CVD) at the highest risk.
- Insulin resistance and associated metabolic abnormalities are central to type 2 diabetes and metabolic syndrome, contributing to atherogenic dyslipidemia and elevated cardiovascular risk.
- Defects in mitochondrial oxidative phosphorylation are implicated in the development of insulin resistance, potentially influenced by genetics, aging, and lifestyle factors.
Purpose of the Study:
- To explore the role of insulin resistance in cardiovascular risk stratification.
- To identify therapeutic strategies targeting insulin resistance to reduce cardiovascular risk.
- To evaluate the efficacy of interventions including lifestyle modifications, fibrates, and statin-fibrate combination therapy.
Main Methods:
- Analysis of clinical trial data to understand cardiovascular risk distribution.
- Review of evidence linking mitochondrial function to insulin resistance.
- Assessment of the impact of various pharmacological and lifestyle interventions on lipid profiles and cardiovascular outcomes in insulin-resistant populations.
Main Results:
- A clear cardiovascular risk pyramid exists, with diabetic patients with CVD at the apex.
- Therapeutic strategies aimed at improving insulin sensitivity, such as diet, exercise, omega-3 fatty acids, and fibrates, can reverse mitochondrial dysfunction and reduce risk.
- While statins offer benefits, residual cardiovascular risk persists in insulin-resistant patients; fibrates and combination therapy show promise in high-risk groups.
Conclusions:
- Insulin resistance is a key factor in the pathogenesis of cardiovascular disease, particularly in patients with type 2 diabetes and metabolic syndrome.
- Targeting insulin resistance through lifestyle interventions and pharmacotherapy, including fibrates and potentially statin-fibrate combinations, is crucial for managing cardiovascular risk.
- Aggressive management of blood pressure and glucose levels alongside lipid modification is essential for this high-risk population.
Abstract:
Trials have revealed that cardiovascular risk is not uniform in the population, but is distributed in a "risk pyramid." Diabetic patients with prior cardiovascular disease (CVD) are at greatest risk. Nondiabetic patients with CVD, diabetic patients without CVD, and subjects with the metabolic syndrome form the next three risk categories. The presence of insulin resistance-related metabolic abnormalities is a common denominator in this risk pyramid. Insulin resistance is a core defect in type 2 diabetes and the metabolic syndrome. Because insulin resistance may cause the atherogenic dyslipidemia that is commonly associated with these conditions, therapeutic strategies that combat insulin resistance could substantially reduce cardiovascular risk. Evidence suggests that defects in mitochondrial oxidative phosphorylation (which may be inherited, age related, or lifestyle acquired) may play a critical role in the pathogenesis of insulin resistance. Reduced mitochondrial oxidative phosphorylation can be partially reversed by improved diet, increased exercise, and administration of peroxisome proliferator-activated receptor-alpha agonists (omega-3 fatty acids and fibrates). Statin therapy has demonstrated clinical benefits in insulin-resistant patients but residual cardiovascular risk remains elevated. Fibrates also improve the lipid profile and reduce cardiovascular risk in a variety of insulin-resistant populations. Affected individuals should be targeted for therapeutic lifestyle intervention. Patients with atherogenic dyslipidemia who have developed insulin resistance, the metabolic syndrome, or type 2 diabetes should receive more intensive interventions including, where appropriate, statin-fibrate combination therapy, to comprehensively modify the lipid profile together with aggressive control of blood pressure and glucose to minimize risk in this very high-risk population.
Related Concept Videos
01:29Cholesterol: Significance and Regulation
Considering cholesterol and...
01:24Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
01:30Coronary Artery Disease I: Introduction
01:24Type II Diabetes II: Pathophysiology
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:26Atherosclerosis III: Management